# Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

> **NCT00363467** · NA · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 3 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** G-CSF
- **DRUG:** Leukapheresis
- **DRUG:** Busulfan
- **PROCEDURE:** Stem cell reinfusion

## Key facts

- **NCT ID:** NCT00363467
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363467, "Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00363467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*